Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
P I3 K inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2018
gptkb:FDA |
| gptkbp:brand |
Copiktra
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
active infections
severe liver impairment |
| gptkbp:developed_by |
gptkb:Verastem,_Inc.
|
| https://www.w3.org/2000/01/rdf-schema#label |
duvelisib
|
| gptkbp:ingredients |
C22 H24 N6 O3 S
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
follicular lymphoma |
| gptkbp:lifespan |
approximately 5-7 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash neutropenia |
| gptkbp:type_of |
1446780-36-1
|
| gptkbp:bfsParent |
gptkb:Calquence
|
| gptkbp:bfsLayer |
4
|